the aid library

Sort by:

Direction:

Download (400)

View PDF (1143)

India: National List of Essential Medicines 2015

Ministry of Health & Family Welfare (MOHFW), Government of India (2015) C_WHO

Download (1987)

View PDF (857)

Liste Nationale des Médicaments et Consommables Medicaux Essentiels Burkina Faso

Ministere de la Sante, Burkina Faso (2020) C_WHO

Liste nationale

Download (735)

View PDF (2145)

Nepal: National List of Essential Medicines, 2021
recommended

World Health Organisation (WHO) (2021) C_WHO

6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.

Download (1869)

View PDF (2800)

Botswana Essential Drug List (BEDL)

Botswana Essential Drug Action Programme (BEDAP), Ministry of Health, Republic of Botswana (2012) C2

Second Edition, 2012

Download (2042)

View PDF (1413)

Liste nationale des médicaments essentiels, République Démocratique du Congo 2020

Ministère de la Santé Publique, DRC (2020) C1

Révison Oct 2020

Download (164)

View PDF (168)

Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19
recommended

Robert-Koch-Institut RKI (2021) C1

16.7.2021

Download (129)

View PDF (131)

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I... more

Download (210)

View PDF (244)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (100)

View PDF (128)

Notes on the identification, diagnosis and treatment of patients with COVID-19
recommended

Robert-Koch-Institut RKI (2021) C1

16.7.2021

Download (76)

View PDF (105)

Myocarditis and pericarditis after mRNA COVID-19 vaccination in children: Interim guidance

SickKids (2020) CC

Download (84)

View PDF (116)

Nota Tecnica Nº 1057/2021-CGPNI/DEIDT/SVS/MS

Ministerio da Saude, Brasilia (2021) CC

Dispõe sobre orientações para identificação, investigação e manejo do evento adverso pós vacinação de miocardite/pericardite no contexto da vacinação contra a COVID-19 no Brasil

Download (110)

View PDF (270)

COVID-19 Guidelines Module 5 - Drug therapy

National Department of Health, South Africa NDoH South Africa (2021) CC

Download (163)

View PDF (125)

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Download (102)

View PDF (148)

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended

Pan American Health Organisation PAHO (2022) C_WHO

This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up... more

Download (83)

View PDF (377)

Guías de tratamiento farmacológico y manejo de escenarios clínicos de casos de COVID-19

Sociedad Paraguaya de Infectologia (SPI) SPI (2022) C2

Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más

Download (70)

View PDF (100)

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Download (124)

View PDF (154)

Antimicrobial Resistance in Food-Animal Production INDIA OVERVIEW

Action on Anitbiotic Resistance (ReAct) (2018) C2

Indian markets caused a stir across the country.1 According to the Centre for Science and the Environment (CSE), a respected New Delhi-based NGO, most honey brands sold in India contained varying amounts of antibiotics. Their consumption over time could induce resistance to antibiotics, putting p... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (23)

View PDF (22)

Epidemiology of Peripheral Artery Disease and Polyvascular Disease

Aday A.W.; Matsushita, K. Circulation Research (2021) CC

Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ... more

Download (51)

View PDF (56)

Kenya National Guidelines for Cardiovascular Diseases Management

Ministry of Health Kenya Republic of Kenya (2018) CC

The Kenya Health Policy 2014-2030 aims at attaining the highest possible standard of health in a manner responsive to the health needs of our population. One of the major policy directions towards realizing the intentions of this policy is to halt and reverse the rising burden of non-communicable d... more

Nepal: National List of Essential Medicines, 2021 recommended

Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19 recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Notes on the identification, diagnosis and treatment of patients with COVID-19 recommended

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022 recommended

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19 recommended